[The effect of metoclopramide, dexamethasone and antihistamine in the prevention of PAC chemotherapy-induced emesis].
The effect of antiemetic agents on the nausea and emesis of ovarian cancer patients treated with CDDP (45 mg/m2), ADM (45 mg/m2) and CPM (450 mg/m2) combination chemotherapy was examined in a randomized parallel study. Metoclopramide (1 mg/kg, 4 times every 2.5 hours), dexamethasone (3.8 mg, 4 times every 2.5 hours) and antihistamine (10 mg, 2 times every 5 hours) were used as antiemetic agents and these agents were gradually decreased for 5 days. The above regimen significantly suppressed the frequency and volume of vomiting on the day of the first PAC chemotherapy but showed no effect on the delayed persistent nausea during chemotherapy. The frequency and volume of vomiting on the day of chemotherapy were 1.6 times and 102 ml respectively in the antiemetic group, but 8.9 times and 352 ml, respectively, in the control group. Although this antiemetic regimen sufficiently suppressed acute drug-induced emesis during chemotherapy, delayed persistent nausea was not eliminated. We next investigated whether these combined antiemetic agents protected the quality of life of patients during maintenance chemotherapy. Our data indicated that about 2 weeks was necessary to recover health after maintenance PAC chemotherapy. These results indicated that this regimen was effective in suppressing the acute drug-induced emesis and in maintaining the quality of life following maintenance PAC chemotherapy.
Kobayashi
H
H
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage*; D004317:Doxorubicin / Q000009:adverse effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006633:Histamine Antagonists / Q000008:administration & dosage*; D006801:Humans; D008787:Metoclopramide / Q000008:administration & dosage*; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011897:Random Allocation; D014839:Vomiting / Q000517:prevention & control*
D006633:Histamine Antagonists; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008787:Metoclopramide; D002945:Cisplatin